These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 17154430)

  • 1. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
    Pan Z; Scheerens H; Li SJ; Schultz BE; Sprengeler PA; Burrill LC; Mendonca RV; Sweeney MD; Scott KC; Grothaus PG; Jeffery DA; Spoerke JM; Honigberg LA; Young PR; Dalrymple SA; Palmer JT
    ChemMedChem; 2007 Jan; 2(1):58-61. PubMed ID: 17154430
    [No Abstract]   [Full Text] [Related]  

  • 2. Bruton's tyrosine kinase as a drug discovery target.
    Pan Z
    Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
    Liu L; Di Paolo J; Barbosa J; Rong H; Reif K; Wong H
    J Pharmacol Exp Ther; 2011 Jul; 338(1):154-63. PubMed ID: 21521773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola.
    Moore WJ; Richard D; Thorarensen A
    Expert Opin Ther Pat; 2010 Dec; 20(12):1703-22. PubMed ID: 21073366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
    Kim KH; Maderna A; Schnute ME; Hegen M; Mohan S; Miyashiro J; Lin L; Li E; Keegan S; Lussier J; Wrocklage C; Nickerson-Nutter CL; Wittwer AJ; Soutter H; Caspers N; Han S; Kurumbail R; Dunussi-Joannopoulos K; Douhan J; Wissner A
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6258-63. PubMed ID: 21958547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis.
    Thakkar M; Bhuniya D; Kaduskar R; Mengawade T; Naik K; Salunkhe V; Bhalerao A; Kurhade S; Mavinahalli J; Jain V; Petla R; Avaragolla S; Ray S; Rouduri S; Dhanave A; De S; Pathade V; Tambe A; Raje AA; Madgula V; Joshi S; Nadeem A; Bala M; Umrani D; Hariharan N; Kulkarni B; Mookhtiar KA
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1867-1873. PubMed ID: 28279528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
    Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
    J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
    Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking.
    Wan HL; Wang ZR; Li LL; Cheng C; Ji P; Liu JJ; Zhang H; Zou J; Yang SY
    Chem Biol Drug Des; 2012 Sep; 80(3):366-73. PubMed ID: 22594639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinases as targets in rheumatoid arthritis.
    Tristano AG
    Int Immunopharmacol; 2009 Jan; 9(1):1-9. PubMed ID: 18848912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
    Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
    Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM
    J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).
    Norman P
    Expert Opin Ther Pat; 2014 Sep; 24(9):979-91. PubMed ID: 24990480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
    Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developments with investigational Janus kinase inhibitors for rheumatoid arthritis.
    Semerano L; Decker P; Clavel G; Boissier MC
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1355-1359. PubMed ID: 27748152
    [No Abstract]   [Full Text] [Related]  

  • 18. Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton's tyrosine kinase inhibitors.
    Zhao X; Xin M; Huang W; Ren Y; Jin Q; Tang F; Jiang H; Wang Y; Yang J; Mo S; Xiang H
    Bioorg Med Chem; 2015 Jan; 23(2):348-64. PubMed ID: 25515957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical potential of targeting Bruton's tyrosine kinase.
    Uckun FM
    Int Rev Immunol; 2008; 27(1-2):43-69. PubMed ID: 18300055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2010 patent landscape for spleen tyrosine kinase inhibitors.
    Moretto AF; Dehnhardt C; Kaila N; Papaioannou N; Thorarensen A
    Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):97-120. PubMed ID: 22292554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.